Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Preview: India's Sun Pharma rises as analysts expect specialty portfolio to power Q2 growth

BUZZ-PREVIEW-India's Sun Pharma rises as analysts expect specialty portfolio to power Q2 growth

** Shares of Sun Pharmaceutical Industries SUN.NS rise 2.9% to 1,812.30 rupees ahead of Q2 results

** Analysts forecast high single-digit to low double-digit revenue growth, led by the India business and specialty portfolio

** Nuvama expects India formulations and specialty drugs to drive another quarter of healthy growth, offsetting weakness in the US business

** Kotak Institutional Equities sees domestic sales remaining robust, while continuing erosion in gRevlimid revenue weighs on US growth

** Motilal Oswal expects specialty therapies including Leqselvi and Winlevi to support revenue momentum despite a softer generic backdrop

** Avg rating of 31 analysts at "buy"; median PT 2,180 rupees - LSEG-compiled data

** YTD, SUN up 5.3% vs pharma index's .NIPHARM nearly 20% climb


(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))

Recent news on Sun Pharmaceutical Industries

See all news